Роль микоплазм в качестве инфекционного агента при канцерогенезе

Обложка

Цитировать

Полный текст

Аннотация

В обзоре представлены данные исследований о роли микоплазм в качестве инфекционных агентов при канцерогенезе, а также их участии в медикаментозной терапии рака и влиянии на исход лечения. Микоплазмы представляют особый интерес, поскольку обладают уникальными способностями легко прикрепляться к эукариотическим клеткам и проникать в них, модулировать их функциональное состояние и вызывать хроническое воспаление, избегая действия иммунной системы хозяина. В обзоре представлены данные, подтверждающие повышенную колонизацию микоплазмами опухолевой ткани по сравнению со здоровой, описаны молекулярные механизмы, с помощью которых микоплазмы активируют экспрессию онкогенов и факторов роста, инактивируют супрессоры опухоли, способствуют NF-κB-зависимой миграции опухолевых клеток и модулируют апоптоз, что приводит к аномальному росту и трансформации клеток хозяина. Также анализируется эффективность противоопухолевых препаратов при микоплазменной инфекции.

Об авторах

М. А. Галямина

ФГБУ «Федеральный научно-клинический центр физико-химической медицины им. акад. Ю. М. Лопухина Федерального медико-биологического агентства»

Автор, ответственный за переписку.
Email: mrogova@gmail.com
ORCID iD: 0000-0002-3216-4320

119435 Москва, ул. Малая Пироговская, 1а

Россия

О. В. Побегуц

ФГБУ «Федеральный научно-клинический центр физико-химической медицины им. акад. Ю. М. Лопухина Федерального медико-биологического агентства»

Email: fake@neicon.ru
ORCID iD: 0000-0001-5265-7627

119435 Москва, ул. Малая Пироговская, 1а

Россия

А. Ю. Горбачев

ФГБУ «Федеральный научно-клинический центр физико-химической медицины им. акад. Ю. М. Лопухина Федерального медико-биологического агентства»

Email: fake@neicon.ru
ORCID iD: 0000-0002-2743-5835

119435 Москва, ул. Малая Пироговская, 1а

Россия

Список литературы

  1. Hansen J.P., Ali W.M., Sivadasan R. et al. Bacteria-cancer interface: awaiting the perfect storm. Pathogens 2021;10(10):1321. doi: 10.3390/pathogens10101321
  2. Liu H.-X., Tao L.-L., Zhang J. et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int J Cancer 2018;142(4):769–78. doi: 10.1002/ijc.31098
  3. Chambers L.M., Bussies P., Vargas R. et al. The microbiome and gynecologic cancer: current evidence and future opportunities. Curr Oncol Rep 2021;23(8):92. doi: 10.1007/s11912-021-01079-x
  4. Littman A.J., Jackson L.A., Vaughan T.L. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005;14(4):773–8. doi: 10.1158/1055-9965.EPI04-0599
  5. Vogelmann R., Amieva M.R. The role of bacterial pathogens in cancer. Curr Opin Microbiol 2007;10(1):76–81. DOI: 10.1016/ j.mib.2006.12.004
  6. Ellmerich S., Scholler M., Duranton B. et al. Promotion of intestinal carcinogenesis by Streptococcus bovis. Carcinogenesis 2000;21(4):753–6. doi: 10.1093/carcin/21.4.753
  7. Touati E. When bacteria become mutagenic and carcinogenic: lessons from H. pylori. Mut Res 2010;703(1):66–70. doi: 10.1016/j.mrgentox.2010.07.014
  8. Scanu T., Spaapen R.M., Bakker J.M. et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe 2015;17(6):763–74. doi: 10.1016/j.chom.2015.05.002
  9. Tsai S., Wear D.J., Shih J.W. et al. Mycoplasmas and oncogenesis: persistent infection and multistage malignant transformation. Proc Nat Acad Sci 1995;92(22):10197–201. doi: 10.1073/pnas.92.22.10197
  10. Razin S., Yogev D., Naot Y. Molecular biology and pathogenicity of mycoplasmas. Microbiol Mol Biol Rev 1998;62(4):1094–56. doi: 10.1128/MMBR.62.4.1094-1156.1998
  11. Kornspan J.D., Tarshis M., Rottem S. Invasion of melanoma cells by Mycoplasma hyorhinis: enhancement by protease treatment. Infect Immun 2010;78(2):611–7. doi: 10.1128/IAI.01017-09
  12. Matyushkina D., Pobeguts O., Butenko I. et al. Phase transition of the bacterium upon invasion of a host cell as a mechanism of adaptation: a Mycoplasma gallisepticum model. Sci Rep 2016;24:6:35959. doi: 10.1038/srep35959
  13. Citti C., Nouvel L.X., Baranowski E. Phase and antigenic variation in mycoplasmas. Future Microbiol 2010;5(7):1073–85. doi: 10.2217/fmb.10.71
  14. Zuo L.L., Wu Y.M., You X.X. Mycoplasma lipoproteins and Tolllike receptors. J Zhejiang Univ Sci B 2009;10(1):67–76. doi: 10.1631/jzus.B0820256
  15. Arfi Y., Minder L., Di Primo C. et al. MIB–MIP is a mycoplasma system that captures and cleaves immunoglobulin G. Proc Natl Acad Sci 2016;113:5406–11. PMID: 27114507. doi: 10.1073/pnas.1600546113.
  16. Grover R.K., Zhu X., Nieusma T. et al. A structurally distinct human mycoplasma protein that genericallyblocks antigen-antibody union. Science 2014;343(6171):656–61. doi: 10.1126/science.1246135
  17. Hayflick L., Koprowski H. Direct agar isolation of Mycoplasmas from human leukaemic bone marrow. Nature 1965;205(4972):713–4. doi: 10.1038/205713b0
  18. Sasaki H., Igaki H., Ishizuka T. et al. Presence of Streptococcus DNA sequence in surgical specimens of gastric cancer. Japanese J Cancer Res 1995;86(9):791–4. doi: 10.1111/j.1349-7006.1995.tb03086.x
  19. Huang S., Li J.Y., Wu J. et al. Mycoplasma infections and different human carcinomas. World J Gastroenterol 2001;7(2):266–9. doi: 10.3748/wjg.v7.i2.266
  20. Ji J.-F., Zhang J., Shou C.-C. et al. Mycoplasma hyorhinis in gastric cancer. Chinese J Cancer Res 2002;14(2):84–7. doi: 10.1007/s11670-002-0019-2
  21. Nascimento Araujo C.D., Amorim A.T., Barbosa M.S. et al. Evaluating the presence of Mycoplasma hyorhinis, Fusobacterium nucleatum, and Helicobacter pylori in biopsies of patients with gastric cancer. Infect Agent Cancer 2021;16(1):70. doi: 10.1186/s13027021-00410-2
  22. Quirk J.T., Kupinski J.M., DiCioccio A.R. Detection of Mycoplasma ribosomal DNA sequences in ovarian tumors by nested PCR. Gynecol Oncol 2001;83(3):560–2. doi: 10.1006/gyno.2001.6446
  23. Chan P.J., Seraj I.M., Kalugdan T.H. et al. Prevalence of mycoplasma conserved DNA in malignant ovarian cancer detected using sensitive PCR-ELISA. Gynecol Oncol 1996;63(2):258–60. doi: 10.1006/gyno.1996.0316
  24. Banerjee S., Tian T., Wei Z. et al. The ovarian cancer oncobiome. Oncotarget 2017;8(22):36225–45. doi: 10.18632/oncotarget. 16717
  25. Klein C., Samwel K., Kahesa C. et al. Mycoplasma сo-infection is associated with cervical cancer risk. Cancers (Basel) 2020;12(5):1093. doi: 10.3390/cancers12051093
  26. Erturhan S.M., Bayrak O., Pehlivan S. et al. Can mycoplasma contribute to formation of prostate cancer? Int Urol Nephrol 2013;45(1):33–8. doi: 10.1007/s11255-012-0299-5
  27. Saadat S., Karami P., Jafari M. et al. The silent presence of Mycoplasma hominis in patients with prostate cancer. Pathog Dis 2020;78(7):ftaa037. doi: 10.1093/femspd/ftaa037
  28. Miyake M., Ohnishi K., Hori S. et al. Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: detection using prostatectomy and needle biopsy specimens. Cells 2019;8(3):212. doi: 10.3390/cells8030212
  29. Barykova Y.A., Logunov D.Y., Shmarov M.M. et al. Association of Mycoplasma hominis infection with prostate cancer. Oncotarget 2011;2(4):289–97. doi: 10.18632/oncotarget.256
  30. Yow M.A., Tabrizi S.N., Severi G. et al. Detection of infectious organisms in archival prostate cancer tissues. BMC Cancer 2014;14:579. doi: 10.1186/1471-2407-14-579
  31. Abdul-Wahab O.M.S., Al-Shyarba M.H., Mardassi B.B.A. et al. Molecular detection of urogenital mollicutes in patients with invasive malignant prostate tumor. Infect Agent Cancer 2021;16(1):6. doi: 10.1186/s13027-021-00344-9
  32. Uphoff C.C., Drexler H.G. Detection of mycoplasma in leukemialymphoma cell lines using polymerase chain reaction. Leukemia 2002;16(2):289–93. doi: 10.1038/sj.leu.2402365
  33. Zhang S., Tsai S., Lo S.-C. Alteration of gene expression profiles during mycoplasma-induced malignant cell transformation. BMC Cancer 2006;6(1):116. doi: 10.1186/1471-2407-6-116
  34. Yacoub E., Saed Abdul-Wahab O.M., Al-Shyarba M.H. et al. The relationship between mycoplasmas and cancer: is it fact or fiction? Narrative review and update on the situation. J Oncol 2021;2021:9986550. doi: 10.1155/2021/9986550
  35. Zhang B., Shih J.W., Wear D.J. et al. High-level expression of H-ras and c-myc oncogenes in mycoplasma-mediated malignant cell transformation. Proc Soc Exp Biol Med 1997;214:359–66. doi: 10.3181/00379727-214-44104
  36. Полянская Г.Г., Ефремова Т.Н., Эндер Н.А. Влияние микоплазменной контаминации клеточной линии лейомиосаркомы человека SK-UT-IB на кариотипическую структуру. Цитология 1998;40(1):23–30.
  37. Jiang S., Zhang S., Langenfeld J. et al. Mycoplasma infection transforms normal lung cells and induces bone morphogenetic protein 2 expression by post-transcriptional mechanisms. J Cell Biochem 2008;104(2):580–94. doi: 10.1002/jcb.21647
  38. Ji Y., Karbaschi M., Cooke M.S. Mycoplasma infection of cultured cells induces oxidative stress and attenuates cellular base excision repair activity. Mut Res 2019;845:403054. doi: 10.1016/j.mrgentox.2019.05.010
  39. Feng S.-H., Tsai S., Rodriguez J., Lo S.-C. Mycoplasmal infections prevent apoptosis and induce malignant transformation of interleukin-3-dependent 32D hematopoietic cells. Mol Cell Biol 1999;19(12):7995–8002. doi: 10.1128/mcb.19.12.7995
  40. Liu W., Shou C. Mycoplasma hyorhinis and Mycoplasma fermentans induce cell apoptosis and changes in gene expression profiles of 32D cells. Biol Res 2011;44(4):383–91.
  41. Logunov D.Y., Scheblyakov D.V., Zubkova O.V. et al. Mycoplasma infection suppresses p53, activates NF-κB and cooperates with oncogenic Ras in rodent fibroblast transformation. Oncogene 2008;27(33):4521–31. doi: 10.1038/onc.2008.103
  42. Wang Y., Wang G., Hong X. et al. Downregulated mitochondrial transcription factor A enhances mycoplasma infection to promote the metastasis of hepatocellular carcinoma. Cancer Sci 2023;114(4):1464–78. doi: 10.1111/cas.15715
  43. Liu X., Rong Z., Shou C. Mycoplasma hyorhinis infection promotes gastric cancer cell motility via β‐catenin signaling. Cancer Med 2019;8(11):5301–12. doi: 10.1002/cam4.2357
  44. Goodison S., Nakamura K., Iczkowski K.A. et al. Exogenous mycoplasmal p37 protein alters gene expression, growth and morphology of prostate cancer cells. Cytogenet Genome Res 2007;118(2–4):204–13. doi: 10.1159/000108302
  45. Zhang Y., Zhang H., Sun X. et al. Nucleic acid aptamer controls mycoplasma infection for inhibiting the malignancy of esophageal squamous cell carcinoma. Mol Ther 2022;30(6):2224–41. doi: 10.1016/j.ymthe.2022.02.018
  46. Benedetti F., Cocchi F., Latinovic O.S. et al. Role of mycoplasma chaperone DnaK in cellular transformation. Int J Mol Sci 2020;21(4):1311. doi: 10.3390/ijms21041311
  47. Xu Y., Li H., Chen W. et al. Mycoplasma hyorhinis activates the NLRP3 inflammasome and promotes migration and invasion of gastric cancer cells. PLoS One 2013;8(11). doi: 10.1371/journal.pone.0077955.e77955
  48. Choo Q.W.W., Koean R.A.G., Chang S.C. et al. Macrophages protect mycoplasma-infected chronic myeloid leukemia cells from natural killer cell killing. Immunol Cell Biol 2020;98(2):138–51. doi: 10.1111/imcb.12309
  49. Namiki K., Goodison S., Porvasnik S. et al. Persistent exposure to mycoplasma induces malignant transformation of human prostate cells. PLoS One 2009;4(9):e6872. doi: 10.1371/journal.pone.0006872
  50. Karampelas T., Skavatsou E., Argyros O. et al. Gemcitabine based peptide conjugate with improved metabolic properties and dual mode of efficacy. Mol Pharm 2017;14(3):674–85. doi: 10.1021/acs.molpharmaceut.6b00961
  51. Emons G., Gorchev G., Sehouli J. et al. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the AGO-study group (AGO GYN 5). Gynecol Oncol 2014;133(3):427–32. doi: 10.1016/j.ygyno.2014.03.576
  52. Cronauer M.V., Klocker H., Talasz H. et al. Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells. Prostate 1996;28(3):172–81. doi: 10.1002/(SICI)10970045(199603)28:3<172::AID-PROS4>3.0.CO;2-H
  53. Parker W.B. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009;109(7):2880–93. doi: 10.1021/cr900028p
  54. Bronckaers A., Balzarini J., Liekens S. The cytostatic activity of pyrimidine nucleosides is strongly modulated by Mycoplasma hyorhinis infection: implications for cancer therapy. Biochem Pharmacol 2008;76(2):188–97. doi: 10.1016/j.bcp.2008.04.019
  55. Liekens S., Bronckaers A., Perez-Perez M.J. et al. Targeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy. Biochem Pharmacol 2007;74(11):1555–67. doi: 10.1016/j.bcp.2007.05.008
  56. Vande Voorde J., Gago F., Vrancken K. et al. Characterization of pyrimidine nucleoside phosphorylase of Mycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues. Biochem J 2012;445(1):113–23. doi: 10.1016/j.bcp.2008.04.019
  57. Jetté L., Bissoon-Haqqani S., Le François B. et al. Resistance of colorectal cancer cells to 5-FUdR and 5-FU caused by Mycoplasma infection. Anticancer Res 2008;28(4B):2175–80.
  58. Ishikawa T., Kamimura H., Tsuchiya A. et al. Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer. Hepatogastroenterology 2007;54(80):2378–82.
  59. Johnson S.M. The importance of B-cells and ecto-5’nucleotidase in Mycoplasma fermentans infection and the relevance to rheumatoid arthritis. Immunology 2008;123(2):187–96. doi: 10.1111/j.1365-2567.2007.02686.x
  60. Merkenschlager M., Kardamakis D., Rawle F.C. et al. Rate of incorporation of radiolabelled nucleosides does not necessarily reflect the metabolic state of cells in culture: effects of latent mycoplasma contamination. Immunology 1988;63(1):125–31.
  61. Fisunov G.Y., Pobeguts O.V., Ladygina V.G. et al. Thymidine utilisation pathway is a novel phenotypic switch of Mycoplasma hominis. J Med Microbiol 2022;71(1):001468. doi: 10.1099/jmm.0.001468
  62. Rakovskaya I.V., Ermolaeva S.A., Levina G.A. et al. Microcolonies: a novel morphological form of pathogenic Mycoplasma spp. J Med Microbiol 2019;68(12):1747–58. doi: 10.1099/jmm.0.001081
  63. Ishikawa F., Miyazono K., Hellman U. et al. Identification of angiogenic activity and the cloning and expression of plateletderived endothelial cell growth factor. Nature 1989;338(6216):557–62. doi: 10.1038/338557a0
  64. Akiyama S., Furukawa T., Sumizawa T. et al. The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 2004;95(11):851–7. doi: 10.1111/j.1349-7006.2004. tb02193.x

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.